MX2020012245A - Sindrome de choque toxico estreptococico. - Google Patents

Sindrome de choque toxico estreptococico.

Info

Publication number
MX2020012245A
MX2020012245A MX2020012245A MX2020012245A MX2020012245A MX 2020012245 A MX2020012245 A MX 2020012245A MX 2020012245 A MX2020012245 A MX 2020012245A MX 2020012245 A MX2020012245 A MX 2020012245A MX 2020012245 A MX2020012245 A MX 2020012245A
Authority
MX
Mexico
Prior art keywords
shock syndrome
toxic shock
protein
streptococcal toxic
antibody
Prior art date
Application number
MX2020012245A
Other languages
English (en)
Inventor
Manisha Pandey
Michael Good
Original Assignee
Univ Griffith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2018901709A external-priority patent/AU2018901709A0/en
Application filed by Univ Griffith filed Critical Univ Griffith
Publication of MX2020012245A publication Critical patent/MX2020012245A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporcionan en la presente métodos para inmunizar, tratar o prevenir el síndrome de choque tóxico estreptocócico en un sujeto, mediante la administración de una proteína M de estreptococo del grupo A, que incluye fragmentos, variantes o derivados de la misma, o un anticuerpo que se une o se genera contra la proteína M y, opcionalmente, una proteína superantígeno de estreptococo del grupo A, que incluye fragmentos, variantes o derivados de la misma, o un anticuerpo o fragmento de anticuerpo que se une, o se genera contra, la proteína superantígeno.
MX2020012245A 2018-05-16 2019-05-16 Sindrome de choque toxico estreptococico. MX2020012245A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2018901709A AU2018901709A0 (en) 2018-05-16 Streptococcal toxic shock syndrome
AU2018904377A AU2018904377A0 (en) 2018-11-16 Streptococcal toxic shock syndrome
PCT/AU2019/050469 WO2019218022A1 (en) 2018-05-16 2019-05-16 Streptococcal toxic shock syndrome

Publications (1)

Publication Number Publication Date
MX2020012245A true MX2020012245A (es) 2021-01-29

Family

ID=68539133

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012245A MX2020012245A (es) 2018-05-16 2019-05-16 Sindrome de choque toxico estreptococico.

Country Status (11)

Country Link
US (1) US20210292398A1 (es)
EP (1) EP3806896A4 (es)
JP (1) JP2021523908A (es)
KR (1) KR20210010882A (es)
CN (1) CN112449603A (es)
AU (1) AU2019268417A1 (es)
BR (1) BR112020023128A2 (es)
CA (1) CA3100212A1 (es)
MX (1) MX2020012245A (es)
SG (1) SG11202011348YA (es)
WO (1) WO2019218022A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4214230A1 (en) * 2020-09-18 2023-07-26 Tanea Medical AB Antibodies against streptococcal m protein

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024910A2 (en) * 1996-12-06 1998-06-11 Regents Of The University Of Minnesota Mutants of streptococcal toxin c and methods of use
DE69737032D1 (de) * 1996-12-06 2007-01-11 Univ Minnesota Mutanten von streptococcaltoxinen und vefahren zu deren anwendung
US6075119A (en) * 1997-04-07 2000-06-13 The Rockefeller University Peptides useful for reducing symptoms of toxic shock syndrome
US20050010034A1 (en) * 1997-12-05 2005-01-13 Regents Of The University Of Minnesota Mutants of streptococcal toxin C and methods of use
ATE557041T1 (de) * 2001-05-18 2012-05-15 Us Gov Health & Human Serv Peptid-vakzinen gegen streptokokken der gruppe a
US20090010929A1 (en) * 2006-12-04 2009-01-08 Good Michael F Therapeutic Antibodies, Antibody Fragments and Antibody Conjugates
US20090162369A1 (en) * 2007-12-12 2009-06-25 Katin Helena Threse Nordstrom Synthetic chimeric peptides

Also Published As

Publication number Publication date
KR20210010882A (ko) 2021-01-28
JP2021523908A (ja) 2021-09-09
BR112020023128A2 (pt) 2021-02-02
AU2019268417A1 (en) 2020-12-03
EP3806896A1 (en) 2021-04-21
CA3100212A1 (en) 2019-11-21
CN112449603A (zh) 2021-03-05
SG11202011348YA (en) 2020-12-30
WO2019218022A1 (en) 2019-11-21
US20210292398A1 (en) 2021-09-23
EP3806896A4 (en) 2022-06-29

Similar Documents

Publication Publication Date Title
MX2024008677A (es) Conjugados de camptotecina.
EP3689909A4 (en) Tigit antibody, antigen-binding fragment thereof, and medical use thereof
ZA201904218B (en) Anti¿ccr7 antibody drug conjugates
EP4344706A3 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
EA201991157A1 (ru) Доставка белков на основе бактерий, аттенуированных по вирулентности
JO3559B1 (ar) جسم مضاد لعلاج أو الوقاية من الصداع النصفي وطريقة استخدامه
TW201613575A (en) Treatment of polybacterial infections
MX2019015516A (es) Anticuerpos de union a il-1beta para el uso en el tratamiento del cancer.
EP3882268A4 (en) ANTI-CD73 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND APPLICATION THEREOF
MX2021002910A (es) Vacunas neumococicas multivalentes.
EP3712170A4 (en) CD96 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF
IL275798A (en) Methods for antibody drug conjugation, purification and formulation
MX2021004173A (es) Combinaciones de anticuerpos dirigidos contra staphylococcus aureus.
MX2019011624A (es) Metodos y composiciones para la reduccion de la inmunogenicidad.
ZA202206993B (en) Anti-lilrb1 antibody and uses thereof
WO2017075188A3 (en) Methods of using anti-alpha toxin antibody
EP4079760A3 (en) Antibodies against clostridium difficile toxins and methods of using the same
MX2021009105A (es) Toxinas apxia, apxiia y apxiiia inactivadas.
WO2018089807A3 (en) Anti-cd46 antibodies and methods of use
MX2019009546A (es) Anticuerpos anti-factor d y uso de los mismos.
EP3587452A4 (en) ANTI-TIM-3 ANTIBODIES, ANTIGEN BINDING FRAGMENT OF IT, AND MEDICAL USES OF IT
WO2018027124A8 (en) ANTI-O2 ANTIBODIES AND USES THEREOF
WO2016145385A3 (en) Pan-ebola and pan-filovirus protective epitopes, antibodies, and antibody cocktails
MX2023002805A (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicacion de los mismos.
EP3919516A4 (en) ANTI-CD79B ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF